Tue, Mar 3, 2015, 11:17 AM EST - U.S. Markets close in 4 hrs 43 mins


% | $
Quotes you view appear here for quick access.

Human Genome Sciences Inc. Message Board

  • biotechboygenius biotechboygenius Jul 4, 2006 5:00 PM Flag

    GTCB is worth a look....I promise!!

    You'll be impressed at the potential. Also, check out Investors Hub - Biotech values for more details.

    gtcb from rodman

    ATRYN RECEIVES POSITIVE CHMP OPINION GTC Biotherapeutics announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion on the market authorization application (MAA) for ATryn for the prophylaxis of venous thromboembolism surgery of patients with
    congenital antithrombin deficiency. ATryn may be given in combination with heparin or low molecular weight heparin, which are used during these surgeries. EMEA routinely accepts recommendation of CHMP. Therefore, we expect final market authorization by the E.U. in about three months. ATryn, once approved, will be the first antithrombin product approved for use in all 25 countries of the E.U.


    The positive CHMP opinion is an
    unusual reversal following a review of GTC's petition of re-examination of a prior negative opinion. While congenital antithrombin deficiency is a very small indication from which GTCB will not derive significant commercial value, ATyn approval is in fact a milestone achievement for GTCB. This is the first time ever that a transgenic goat product is approved for any indication, which serves to validate GTCB's proprietary technology platform. LEO Pharma, GTCB's
    European partner, will be responsible for the commercialization of ATryn in the E.U. for the approved indication and has selected
    disseminated intravascular coagulation (DIC) as an acquired antithrombin deficiency indication to develop a large market opportunity for ATryn in the E.U. Leo is expected to start a Phase II trial by YE06. Future success of ATryn in an acquired indication will be critical to the long-term prospects of GTCB. Raising GTCB to Market outPerform We are greatly encouraged by the
    reversal of CHMP's opinion regarding the approvability of ATryn. It not only validates the technology platform but also greatly increases our confidence in the company management's ability to execute with regard to regulatory maters. We are strong believers in GTCB's technology platform and expect more companies to adopt it as a way to produce complicated protein therapeutics. We believe the decision by Leo Pharm to move forward with ATryn in DIC, a large acquired antithrombin deficiency indication, is definitely a positive development for GTCB. Using the sales multiple of 6X our 2013 ATryn
    revenue estimate of approximately $226 MM and a 30% annual discount rate that we believe adequately compensates investors for the risks
    associated with GTCB, we derive a 12-month price target of $4.

    KEY RISK US ATryn trial setback

    Navdeep S. Jaikaria, Ph.D.
    Managing Director
    Senior Biotechnology Analyst
    212 356 0538


Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.